Research Reports

Key takeaways

Theodora Mistras appointed CFO effective May 29, 2026, succeeding Scott Ullem.

Compensation includes $925,000 annual salary, 100% target bonus, and $2,013,000 sign-on bonus.

Initial RSU grant of $8,000,000 vests over three years with accelerated vesting on qualifying termination.

Annual equity grant for FY2026 valued at $4,500,000.

Severance benefits include at least 1x salary plus 1x bonus under Leadership Committee plan.

Relocation benefits and up to $15,000 legal fee reimbursement provided.

Full analysis

Edwards Lifesciences announced the appointment of Theodora Mistras as Corporate Vice President and Chief Financial Officer, effective May 29, 2026. Mistras brings extensive healthcare finance experience from her roles as CFO of Viatris and managing director at Citigroup and Goldman Sachs. The transition follows Scott Ullem's planned departure after serving as CFO since 2014. The compensation package is designed to attract and retain top executive talent, with a significant sign-on bonus and equity incentives that align with long-term shareholder value. The accelerated vesting provisions on the RSU grant provide retention and protection in case of qualifying termination. This executive change is material as the CFO role is critical to the company's financial strategy and investor relations.

EW · Edwards Lifesciences Corporation

Summary

Key takeaways

Full analysis